Fund moves
From a 13F filed Nov 16, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
AMGN · NASDAQ · Biotechnology
Amgen (AMGN) · oqro.io/stocks/AMGN · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
Baskets of the companies that insiders, members of Congress or funds recently reported buying, each held under a written rule.
$435.64−3.18 (−0.72%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
No open-market purchase by an insider of Amgen was filed in the last 90 days. The latest on record was on Aug 19, 2015.
Since 2006, Amgen insiders reported 9 open-market purchases and 512 sales on Forms 4 and 5, with purchases in 7 different years, most recently 2015.
No open-market sale by an insider of Amgen (AMGN) was filed with the SEC in the last 90 days.
Yes. Members of Congress disclosed 17 trades in Amgen (AMGN) in the last 12 months, each reported as a value range on a periodic transaction report. The most recent are from Rep. David J. Taylor (OH02), Sen. Sheldon Whitehouse, Sen. Alan Armstrong and 2 other members.
Amgen's next results are expected on Feb 1, 2027, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
+29.6% (+$99.57) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
Adjusted close went from $336.07 on Nov 20, 2025 to $435.64 on Nov 20, 2026 (+29.6%). Disclosed in this range: 2 insider trades, 10 pre-arranged insider sales, 15 Congress trades, and 208 13F position changes for 4 quarters ending in it.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Biotechnology company based in Thousand Oaks, California.
Last 12 months
+29.6%
Market value
$248B
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 12.6M shares sold short (2.2% of shares outstanding), −5.9% vs the previous count, 5.0 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Revenue, fiscal 2025
$36.8B
+10.0% vs the year before
Net income, fiscal 2025
$7.71B
As reported in the annual filing
Shares outstanding
541M
As of Oct 29, 2026
In fiscal 2025 the company spent $5.12B on dividends. Cash actually paid, from its cash-flow statement.
Last dividend: $2.52 a share (quarterly), ex-date Nov 20, 2026, payable Dec 11, 2026. Calendar
Fund moves
From a 13F filed Nov 16, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Traded Nov 3, 2026 · disclosed 9 days later
Nov 3, 2026$1,001–$15,000
DetailsOfficial recordNov 3, 2026$1,001–$15,000
DetailsOfficial recordCongress
Traded Sep 22 · disclosed 9 days later
Since the trade +6.2% · S&P 500 −10.8% · to Nov 20
Bought 8% below the 52-week high, RSI 54, 14% above its 200-day average, 13 points ahead of the S&P 500 over 3 months
2 different filers disclosed AMGN within 90 days.
Congress
Traded Aug 26 · disclosed 10 days later
Since the trade −1.1% · S&P 500 −10.0% · to Nov 20
2 different filers disclosed AMGN within 90 days.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Revenue
$10.4B
+8.5% vs the same quarter a year earlier
Free cash flow, last 12 months
$9.58B
This quarter $3.65B, a year earlier $4.25B
Net debt
$40.8B
Debt $54B, cash $13.2B, at Sep 30, 2026
Net income, last 12 months
$9.39B
Operating profit covers interest 4.78x
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 3, 2026.
Revenue and earnings history, 19 fiscal yearsRevenue breakdown: where the money goesCompared with its peersEarnings dates and the stock's moves
Insiders of Amgen reported 9 open-market purchases and 512 sales since 2006; purchases in 7 different years, most recently 2015.
| Year | Bought | Sold |
|---|---|---|
| 2026 | — | $25.7M10×10 trades |
| 2025 | — | $28.6M15×15 trades |
| 2024 | — | $663K1×1 trade |
| 2023 | — | $5.81M3×3 trades |
| 2022 | — | $5.38M6×6 trades |
| 2021 | — | $4.59M9×9 trades |
| 2020 | — | $3.64M10×10 trades |
| 2019 | — | $10.9M17×17 trades |
| 2018 | — | $6.22M9×9 trades |
| 2017 | — | $2.53M6×6 trades |
| 2016 | — | $12.1M5×5 trades |
| 2015 | $730K3×3 trades | $15.8M10×10 trades |
| 2014 | $100K1×1 trade | $5.92M9×9 trades |
| 2013 | — | $14M16×16 trades |
| 2012 | — | $216M58×58 trades |
| 2011 | $53K1×1 trade | $7.31M10×10 trades |
| 2010 | — | $3.59M16×16 trades |
| 2009 | $45K1×1 trade | $16.6M52×52 trades |
| 2008 | $500K1×1 trade | $27.9M111×111 trades |
| 2007 | $142K1×1 trade | $1.22M3×3 trades |
| 2006 | $350K1×1 trade | $19.3M136×136 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Disclosed a material cybersecurity incident
8-K on sec.govTop officer leaving
“Griffith will retire from the role of the Company’s Executive Vice President and Chief Financial Officer, effective August 31, 2026.”
1 insider sold ~$400K in the 60 days before
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
On the public record for Amgen over the 12 months to Nov 19, 2026: 7 FDA records, 24 executive contributions and 67 clinical trials (9th most among listed companies).
Against the S&P 500 over the year
Since Nov 19, 2025, AMGN is up 27.2% and the index fund is up 4.1%: 23 points ahead of the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much AMGN moves
Beta 0.5 (1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 251 trading days (1 = in step with it).
ChemoCentryx, Inc.; Proposal To Withdraw Approval of New Drug Application for TAVNEOS (Avacopan) Capsule, 10 Milligrams; Opportunity for a Hearing
Notice · Food and Drug Administration
Fiduciary Duties in Selecting Designated Investment Alternatives
Proposed rule · Employee Benefits Security Administration
Granting of Requests for Early Termination of the Waiting Period Under the Premerger Notification Rules
Notice · Federal Trade Commission
Aspen Global Inc. c/o Lachman Consultant Services, Inc., et al.; Withdrawal of Approval of 46 New Drug Applications
Notice · Food and Drug Administration
Federal rules, proposed rules and notices that name the company by its legal name, from the Federal Register. Being named is not the same as being the target of a rule.
People read Amgen's Wikipedia article about 220 times a day over the last week, fewer than the 290 on a usual day of the three months before.
May 16, 2026Busiest day: 1,300 views on Sep 13, 2026Nov 21, 2026
Views of the article Amgen, by people (Wikimedia leaves out known bots). More readers means more attention, from news, results or anything else; it does not say anyone bought or sold. Source: Wikimedia pageviews.
Last results
Nov 3, 2026
Within the 30 days after it, until Dec 3, 2026
Next results, expected
Feb 1, 2027
after the market closes; the date can move until the company confirms it
Purchases after results
Not enough history
From Amgen's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Amgen's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Vanguard Capital Management
13G · passive · Crossed 5% · 40.5M shares · filed Apr 29, 2026
Capital World Investors
13G · passive · Crossed 5% · 29.6M shares · filed May 14, 2026
Recent moves
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
181 certified in FY2026 Q3, vs 213 a year earlier. 181 positions in total, median offered wage $140K a year.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
2 approvals or clearances and 5 recalls recorded by the FDA for this company and its listed subsidiaries.
From openFDA: Drugs@FDA (new applications and new uses), device 510(k) and PMA decisions, and FDA enforcement reports. Class I recalls are the most serious, Class III the least. Most recalls are started by the company itself. Labeling and manufacturing changes are not listed.
Latest annual report filed Feb 13, 2026, compared with the one filed Feb 14, 2025. Read the filing
All 28 risk factor headings match the year before, give or take wording.
Certain of the legal proceedings in which we are involved are discussed in Part IV—Note 20, Contingencies and commitments, to the Consolidated Financial Statements and are hereby incorporated by reference.
The company describes its cases in the notes to its financial statements, in the same filing.
Source: SEC EDGAR, Form 10-K filed Feb 13, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Fiscal year Jan 1, 2025 to Dec 31, 2025, from the annual report filed Feb 13, 2026. Read the filing
+11% on the year before ($23.9B)
+8.1% on the year before ($9.56B)
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 12,000 words.
Amgen Inc. (including its subsidiaries, referred to as “Amgen,” “the Company,” “we,” “our” or “us”) discovers, develops, manufactures and delivers innovative medicines to fight some of the world’s toughest diseases. We focus on areas of high unmet medical need and leverage our expertise to strive for solutions that dramatically improve people’s lives, while also reducing the social and economic burden of disease. We helped launch the biotechnology industry more than 45 years ago and have grown to be one of the world’s leading independent biotechnology companies. Our robust pipeline includes potential first-in-class medicines at all stages of development.
And 26 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Feb 13, 2026. Revenue lines are the figures the company tags in its filing; OQRO shows a split only when its lines add up to the reported total revenue. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
Congress
Funds and stakes
Contracts, lobbying and filings
Company reports, price and press
Who holds it
Attention
Things to keep in mind
Records
Short sale volume: 52.8% of the volume reported to FINRA over the last 20 trading days was marked short, close to its 1-year average of 54.7%. FINRA daily files, to Nov 20, 2026.
Fails to deliver: 9,195 shares (about $4.12M) were not delivered on time for settlement on Oct 28, 2026. SEC fails-to-deliver data.
Short sale volume is not short interest. It counts trades marked short, including market makers selling short to fill buy orders, so it is a share of daily trading, not a count of bets against the stock. Fails to deliver have many causes, including processing delays, and are often resolved within days.
Off-exchange trading: 46.0% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (21.3% on ATS, 24.7% with other brokers), above its 26-week average of 43.1%. Weeks of Oct 5 to Oct 30, 2026.
Largest ATS: INTELLIGENT CROSS LLC (15.2%), UBS ATS (13.8%), SIGMA X2 (8.9%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
50 active phase 3 trials and 17 active phase 2 trials led by this company, mostly in obesity, thyroid eye disease, small cell lung cancer (sclc). The ones with the nearest registered primary completion date still ahead:
11 trials have a registered primary completion date that has already passed. That usually means the data are being analyzed, or the entry has not been updated.
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.